A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1

Neuro-Oncology

Volumn 16, Issue 2, 2014, Pages 191-203

  Lee, Jun Sung ^a   Xiao, Jiping ^a   Patel, Parita ^a   Schade, Jake ^a   Wang, Jinhua ^b   Deneen, Benjamin ^c   Erdreich Epstein, Anat ^d   Song, Hae Ri ^a,e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

glioblastoma (GBM); glioma; nuclear factor IA (NFIA); p21; p53; PAI1

Indexed keywords

NUCLEAR FACTOR I; NUCLEAR FACTOR IA PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P21; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN FUNCTION; REGULATORY MECHANISM; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR XENOGRAFT;

GLIOBLASTOMA (GBM); GLIOMA; NUCLEAR FACTOR IA (NFIA); P21; P53; PAI1;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; NFI TRANSCRIPTION FACTORS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893153918     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not167     Document Type: Article

References (57)

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
3. Siebzehnrubl FA,Reynolds BA,Vescovi A, SteindlerDA, Deleyrolle LP. The origins of glioma: E Pluribus Unum? Glia. 2011;59(8):1135-1147.
4. Ligon KL, Huillard E, Mehta S, et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 2007;53(4):503-517.
5. Sun Y, Meijer DH, Alberta JA, et al. Phosphorylation state of Olig2 regulates proliferation of neural progenitors. Neuron. 2011; 69(5):906-917.
6. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 2002;21(55):8404-8413.
7. Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B. Stat3 inhibition activates tumormacrophages and abrogates glioma growth in mice. Glia. 2009;57(13):1458-1467.
8. Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer. 2003;3:23.
9. Gronostajski RM. Roles of the NFI/CTF gene family in transcription and development. Gene. 2000;249(1-2):31-45.
10. Sun P, Dong P, Dai K, Hannon GJ, Beach D. p53-independent role of MDM2 in TGF-beta1 resistance. Science. 1998;282(5397):2270-2272.
11. das Neves L, Duchala CS, Tolentino-Silva F, et al. Disruption of the murine nuclear factor I-A gene (Nfia) results in perinatal lethality, hydrocephalus, and agenesis of the corpus callosum. Proc Natl Acad Sci U S A. 1999;96(21):11946-11951.
12. Shu T, Butz KG, Plachez C, Gronostajski RM, Richards LJ. Abnormal development of forebrain midline glia and commissural projections in Nfia knock-out mice. J Neurosci. 2003;23(1):203-212.
13. Deneen B, Ho R, Lukaszewicz A, Hochstim CJ, Gronostajski RM, Anderson DJ. The transcription factor NFIA controls the onset of gliogenesis in the developing spinal cord. Neuron. 2006;52(6): 953-968.
14. Kang P, Lee HK, Glasgow SM, et al. Sox9 and NFIA coordinate a transcriptional regulatory cascade during the initiation of gliogenesis. Neuron. 2012;74(1):79-94.
15. Scrideli CA, Carlotti CG Jr, Okamoto OK, et al. Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol. 2008;88(3):281-291.
16. Song HR, Gonzalez-Gomez I, Suh GS, et al. Nuclear factor IA is expressed in astrocytomas and is associated with improved survival. Neuro Oncol. 2010;12(2):122-132.
17. Zheng S, Eacker SM, Hong SJ, Gronostajski RM, Dawson TM, Dawson VL. NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. J Clin Invest. 2010;120(7):2446-2456.
18. Plachez C, Lindwall C, Sunn N, et al. Nuclear factor I gene expression in the developing forebrain. J Comp Neurol. 2008;508(3):385-401.
19. Ishii N, Maier D, Merlo A, et al. Frequent co-alterations of TP53, p16/ CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9(3):469-479.
20. Xiong G, Husseiny MI, Song L, et al. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer. 2010; 126(11):2622-2634.
21. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, et al. Novel cell lines established from pediatric brain tumors. J Neurooncol. 2012;107(2): 269-280.
22. Rosol M, Harutyunyan I, Xu J, et al. Metabolism of orthotopic mouse brain tumor models. Mol Imaging. 2009;8(4):199-208.
23. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006;9(4): 287-300.
24. Bredel M, Bredel C, Juric D, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 2005;65(19): 8679-8689.
25. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related self-renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J ClinOncol. 2008;26(18):3015-3024.
26. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1): 98-110.
27. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004;4(8):592-603.
28. Lee HK, Xiang C, Cazacu S, et al. GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis. Neuro Oncol. 2008;10(3):236-243.
29. Sawada M, Nakashima S, Banno Y, et al. Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Cell Death Differ. 2000;7(9):761-772.
30. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49-53.
31. Blagosklonny MV. Loss of function and p53 protein stabilization. Oncogene. 1997;15(16):1889-1893.
32. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268-1286.
33. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene. 2004;23(6):1283-1290.
34. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2(2):a001107.
35. Furlong EE, Rein T, Martin F. YY1 and NF1 both activate the human p53 promoterbyalternatively binding toacompositeelement,andYY1and E1A cooperate to amplify p53 promoter activity. Mol Cell Biol. 1996; 16(10):5933-5945.
36. Johansson EM, Kannius-Janson M, Gritli-Linde A, Bjursell G, Nilsson J. Nuclear factor 1-C2 is regulated by prolactin and shows a distinct expression pattern in the mouse mammary epithelial cells during development. Mol Endocrinol. 2005;19(4):992-1003.
37. Ouellet S, Vigneault F, Lessard M, Leclerc S, Drouin R, Guerin SL. Transcriptional regulation of the cyclin-dependent kinase inhibitor 1A (p21) gene by NFI in proliferating human cells. Nucleic Acids Res. 2006;34(22):6472-6487.
38. Hjortland GO, Bjornland K, Pettersen S, et al. Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1. Clin Exp Metastasis. 2003;20(4):301-309.
39. SmithHW, Marshall CJ.Regulation of cell signalling byuPAR.NatRev Mol Cell Biol. 2010;11(1):23-36.
40. Riccio A, Pedone PV, Lund LR, Olesen T, Olsen HS, Andreasen PA. Transforming growth factor beta 1-responsive element: closely associated binding sites for USF and CCAAT-binding transcription factor-nuclear factor I in the type 1 plasminogen activator inhibitor gene. Mol Cell Biol. 1992;12(4):1846- 1855.
41. Starnes LM, Sorrentino A, Pelosi E, et al. NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression. Blood. 2009; 114(9):1753-1763.
42. Fazi F,Rosa A, Fatica A, et al.Aminicircuitrycomprisedof microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell. 2005;123(5):819-831.
43. Zardo G, Ciolfi A, Vian L, et al. Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood. 2012;119(17):4034-4046.
44. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
45. Johansson EM, Kannius-Janson M, Bjursell G, Nilsson J. The p53 tumor suppressor gene is regulated in vivo by nuclear factor 1-C2 in the mouse mammary gland during pregnancy. Oncogene. 2003;22(38): 6061-6070.
46. Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 2006;20(18):2513-2526.
47. el-DeiryWS,TokinoT,Velculescu VE, et al.WAF1,apotentialmediator of p53 tumor suppression. Cell. 1993;75(4): 817-825.
48. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005;65(10):3980-3985.
49. Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res. 2006; 34(2):543-554.
50. Czekay RP, Wilkins-Port CE, Higgins SP, et al. PAI-1: An Integrator of Cell Signaling and Migration. Int J Cell Biol. 2011;2011:562481.
51. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 1996; 383(6599):441-443.
52. Bindal AK, Hammoud M, Shi WM,Wu SZ, Sawaya R, Rao JS. Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol. 1994;22(2):101-110.
53. Landau BJ, Kwaan HC, Verrusio EN, Brem SS. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res. 1994; 54(4):1105-1108.
54. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res. 1994;54(13): 3329-3332.
55. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des. 2003;9(19):1545-1564.
56. Hjortland GO, Lillehammer T, Somme S, et al. Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells. Exp Cell Res. 2004;294(1):130-139.
57. WangW, Mullikin-Kilpatrick D, Crandall JE, Gronostajski RM, Litwack ED, Kilpatrick DL. Nuclear factor I coordinates multiple phases of cerebellar granule cell development via regulation of cell adhesion molecules. J Neurosci. 2007;27(23):6115-6127.